Parkman Healthcare Partners LLC Immunovant, Inc. Transaction History

Parkman Healthcare Partners LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$14.2 - $23.75 $437,686 - $732,046	30,823 Added 16.57%	216,868 $4.11 Million
Q1 2023 May 12, 2023	BUY	$15.27 - $19.72 $428,155 - $552,929	28,039 Added 17.75%	186,045 $2.89 Million
Q4 2022 Feb 13, 2023	BUY	$6.59 - $17.75 $1.04 Million - $2.8 Million	158,006 New	158,006 $2.8 Million
Q1 2021 May 14, 2021	SELL	$13.08 - $49.6 $795,015 - $3.01 Million	-60,781 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$36.36 - $52.71 $3.25 Million - $4.71 Million	-89,370 Reduced 59.52%	60,781 $2.81 Million
Q3 2020 Nov 13, 2020	BUY	$22.61 - $38.9 $565,837 - $973,511	25,026 Added 20.0%	150,151 $5.28 Million
Q2 2020 Aug 13, 2020	BUY	$13.87 - $28.44 $1.18 Million - $2.42 Million	85,000 Added 211.84%	125,125 $3.05 Million
Q1 2020 May 15, 2020	BUY	$8.36 - $17.13 $335,445 - $687,341	40,125 New	40,125 $625,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.